Şakir

Curium Receives Marketing Authorization in the EU for PYLCLARI™, an Innovative 18F-PSMA PET Tracer Indicated in Adults With Prostate Cancer

Retrieved on: 
Friday, July 28, 2023

Sakir Mutevelic, MD, MSc, Chief Medical Officer at Curium, commented, “We are very pleased to receive marketing authorization in the EU for PYLCLARI™.

Key Points: 
  • Sakir Mutevelic, MD, MSc, Chief Medical Officer at Curium, commented, “We are very pleased to receive marketing authorization in the EU for PYLCLARI™.
  • The successful clinical development and granted marketing authorization of PYLCLARI™ in the EU confirms our mission to redefine the experience of cancer through our trusted legacy in nuclear medicine.
  • When in full production, PYLCLARI™ will be the most widely available 18F-PSMA tracer in Europe.
  • In the U.S., Lantheus received approval for [18F]-DCFPyL, now PYLARIFY® (Piflufolastat F 18 Injection) from the Food and Drug Administration (FDA) in May 2021.

Curium Receives Positive CHMP Opinion of PYLCLARI® for Primary Staging of Patients With High-Risk PCa Prior to Initial Curative Therapy and to Localize Recurrence of PCa in Patients With a Suspected Recurrence Based on Increasing Serum Prostate-Specific A

Retrieved on: 
Friday, May 26, 2023

Sakir Mutevelic, MD, MSc, Chief Medical Officer at Curium commented, “This positive CHMP opinion for PYLCLARI® is an important step forward in our goal of redefining the experience of cancer through our trusted legacy in nuclear medicine.

Key Points: 
  • Sakir Mutevelic, MD, MSc, Chief Medical Officer at Curium commented, “This positive CHMP opinion for PYLCLARI® is an important step forward in our goal of redefining the experience of cancer through our trusted legacy in nuclear medicine.
  • Upon its approval, PYLCLARI® will become available across Europe to help patients along their prostate cancer journey.
  • We are very excited to bring PYLCLARI® to the market and contribute to improving the set of diagnostic tools available to better diagnose and monitor prostate cancer.
  • The CHMP’s positive opinion on PYLCLARI® will be referred to the European Commission, which will deliver a final decision in approximately two months.

Curium is pleased to announce that Sakir Mutevelic MD, MSc has joined as global Chief Medical Officer

Retrieved on: 
Wednesday, December 15, 2021

In this role, he develops and leads Curium`s product pipeline growth initiatives, to drive product evolution and portfolio expansion across radiopharmaceutical diagnostics, companion diagnostics and therapeutics -- ensuring the Curium Group fulfils its “Life Forward” mission to transform and improve disease management and patient lives. This includes managing and coordinating strategic partnerships, clinical development planning and operational execution, managing the clinical aspects of regulatory strategies and interactions with health authorities, and supporting Curium`s strategic initiatives from medical and clinical development perspective. Sakir is a member of Curium’s Global Leadership Team.

Key Points: 
  • London and Paris, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Curium welcomes Sakir Mutevelic MD, MSc.
  • As Chief Medical Officer, Sakir leads Curiums global medical strategy and clinical development for diagnostic and therapeutic radiopharmaceuticals.
  • Sakir is a member of Curiums Global Leadership Team.
  • For more information about this press release, please contact Sandy Borgschulte at [email protected] or 314.954.6637